Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Vioxx

Known as: Merck Frosst brand of rofecoxib, Merck brand of rofecoxib, Merck Sharp & Dhome brand of rofecoxib 
a kind of nonsteroidal anti-inflammatory drugs
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Patricia McGettigan and David Henry find that, although some non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
  • M. Liu, Y. Wu, +5 authors H. Xu
  • J. Am. Medical Informatics Assoc.
  • 2012
  • Corpus ID: 8253194
Objective Adverse drug reaction (ADR) is one of the major causes of failure in drug development. Severe ADRs that go undetected… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
As patients store their personal health information in online repositories, the entities holding this information may be able to… Expand
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Pharmaceutical policy making raises particular challenges in reconciling key objectives for health policy, such as ensuring… Expand
Is this relevant?
Review
2007
Review
2007
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
  • E. Topol
  • The New England journal of medicine
  • 2004
  • Corpus ID: 12516952
On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
  • B. Sibbald
  • Canadian Medical Association Journal
  • 2004
  • Corpus ID: 13140911
Merck & Co. announced Sept. 30 a voluntary worldwide withdrawal of rofecoxib (Vioxx) after a study showed patients taking the… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
The discoveries that cyclooxygenase (COX)-2 is an inducible form of COX involved in inflammation and that COX-1 is the major… Expand
  • table 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?